Company outperforms internal projections while advancing investments, acquisitions, and strengthening its balance sheetVANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (CSE: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company”), a mobile clinical network powered by a proprietary telehealth platform, pharmacy network, and medical director network across 50 states, today provided a corporate update highlighting stronger-than-expected order growth and recent stra ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025(the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to b ...

ToplineThe Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about some of their products, targeting the companies just days after President Donald Trump signed an order designed to clamp down on direct-to-consumer drug advertising.Hims was one of dozens of companies that received the warning letters. (Photo illustration by Cheng Xin/Getty Images)Getty Images ...

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy. ...

SPECIAL REPORT: Here's The Most Trusted Company For Investing Hims stock toppled Tuesday after the Food and Drug Administration issued the telehealth giant a warning letter regarding its knockoff version of Novo Nordisk's semaglutide. The Pressure On Hims Stock Hims & Hers Health is a telehealth giant with a compounding business. The company sells skin care, sexual health and hair-loss products. But Hims became a household name when the company launched its compounded semaglutide in May 2024. At the time, b ...

诉讼背景 - 针对LifeMD公司的新联邦证券欺诈集体诉讼已在纽约东区提起 指控公司及高管在财务健康状况和增长前景方面误导投资者[1] - 诉讼由Hagens Berman律师事务所主导调查 该所在企业问责复杂诉讼领域已累计获得超过29亿美元赔偿[9] 指控内容 - 公司于2025年5月6日发布第一季度业绩时 提高了全年收入和调整后EBITDA指引 并宣称在虚拟肥胖护理领域拥有"定义类别的竞争护城河"[2] - 指控称公司未披露RexMD部门客户获取成本上升以及体重管理业务退款率高于预期等关键业务挑战[3] - 诉讼重点针对2025年5月7日至8月5日期间公司作出的虚假和误导性陈述[2] 股价影响 - 2025年8月5日公司公布第二季度业绩 收入及每股收益未达预期并下调全年指引 次日股价暴跌超过44%[4] - 管理层在业绩电话会上将原因归咎于RexMD业务"暂时性升高的客户获取成本"和体重管理服务的患者退款问题[4] 诉讼程序 - 集体诉讼期间确定为2025年5月7日至8月5日[2] - 主要原告申请截止日期为2025年10月27日[2] - 潜在赔偿对象涵盖在此期间遭受重大损失的投资者[5]

公司业务与市场表现 - 公司是一家远程医疗促进商、药物分销商和GLP-1提供商 业务涵盖远程医疗、药物分销和GLP-1药物供应 [1] - 公司股票近期经历大幅波动 尤其受到零售投资者高度关注 [1] 投资者关注度 - 零售投资者对该股票的兴趣显著增加 成为近期股价波动的主要驱动因素之一 [1]

Hims & Hers Health Inc. HIMS launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.An estimated 20 million men in the U.S. struggle with low testosterone.Bloomberg earlier reported the update. The telehealth company's latest move comes as its weight-loss drug sales have slowed, impacting its stock performance in recent months. The new offerings aim to bolster its core sexual health services and tap into an underserved market ...

Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone. ...

公司业务拓展 - Hims & Hers Health公司通过其远程医疗平台推出低睾酮治疗方案 深入涉足常受污名化影响的医疗类别 [1]